ClinicalTrials.gg
RecruitingNCT07544056Updated Aug 18, 2026

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Phase 2/3 interventional study of BEBT-209 capsules and Carboplatin Injection in Locally Advanced Triple-negative Breast Cancer and Metastatic Triple-negative Breast Cancer, sponsored by BeBetter Med Inc. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by BeBetter Med Inc · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
29th of 235
446 · median 90
Started
2026
with 31 others
Phase 2/3
6 of 252
4 open now
Primary completion
2030-06
later than 148 of 152 live
Registered
241st of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 29th largest by planned enrollment of the 235 interventional ones that give a count, is one of 32 that started in 2026, is one of 6 in phase 2/3, reaches primary completion later than 148 of the 152 other live ones, and was the 241st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

Title: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast cancer. This cancer is called locally advanced or metastatic triple-negative breast cancer (TNBC).

The study has two parts. In the first part, researchers want to see if the new drug combination can shrink tumors. In the second part, researchers want to see if this treatment helps people live longer.

Researchers will put participants into two groups by chance. This is like flipping a coin.

Group 1: Participants get BEBT-209 plus two chemotherapy drugs. These drugs are Carboplatin and Gemcitabine.

Group 2: Participants get only the two chemotherapy drugs. Researchers will group people based on the treatments they had in the past.

Researchers will also check:

How long the treatment keeps the cancer from growing. This is called progression-free survival (PFS).

If the treatment is safe. Researchers will look for adverse events (AE), such as low blood cell counts.

How participants feel. This is called health-related quality of life (HRQoL). How the body uses the drug.

Read the detailed description
  1. Study Overview This is a randomized, controlled, open-label, multi-center, Phase IIb/III study designed to systematically evaluate the efficacy and safety of BEBT-209 (a selective cyclin-dependent kinase 4/6 [CDK4/6] inhibitor) in combination with carboplatin and gemcitabine (CG) compared to CG alone. The study is conducted in patients with locally advanced or metastatic triple-negative breast cancer (TNBC).
  2. The trial is structured into two stages:

    Phase IIb (Proof of Concept): Primarily focused on assessing the objective response rate (ORR) in approximately 60 participants.

    Phase III (Confirmatory): A pivotal stage focused on overall survival (OS) in approximately 386 participants.

  3. Scientific Rationale:

    Triple-negative breast cancer remains a highly aggressive subtype with limited treatment options once initial therapies fail. BEBT-209 acts as a highly selective CDK4/6 inhibitor. By arresting the cell cycle at the G1 phase, BEBT-209 synchronizes tumor cells, making them more susceptible to chemotherapy-induced DNA damage. Preclinical and early-phase clinical data suggest that BEBT-209 not only enhances the sensitivity of TNBC cells to carboplatin and gemcitabine but also provides a myeloprotective effect, reducing chemotherapy-induced bone marrow suppression.

  4. Study Design and Intervention:

    Eligible participants are randomly assigned in a 1:1 ratio to either the experimental group or the control group via a central randomization system.

    Experimental Group: Participants receive BEBT-209 (150 mg, four times per cycle on Day 1 [D1], Day 2 [D2], Day 8 [D8], and Day 9 [D9]) combined with carboplatin (area under the curve [AUC] × [creatinine clearance {CrCl} + 25]) and gemcitabine (1000 mg/m²). The AUC value is set to 2 mg/mL/min in this study.

    Control Group: Participants receive carboplatin (2 [mg/mL/min] × [CrCl {mL/min} + 25]) and gemcitabine (1000 mg/m²) on Day 1 (D1) and Day 8 (D8) of each 21-day cycle.

  5. Stratification Factors:

    Phase IIb: Lines of prior therapy (1st-line vs. 2nd-line). Phase III: (1) Lines of prior systemic therapy; (2) Prior programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1, or PD-[L]1) inhibitor therapy (yes vs. no); (3) Prior TROP2 antibody-drug conjugate (ADC) therapy (yes vs. no).

  6. Assessment and Follow-up:

Tumor response is evaluated every 6 weeks for the first three assessments, then every 9 weeks, and eventually every 12 weeks after one year, based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 criteria.

Independent Review: An independent review committee (IRC) will perform a blinded central review of all imaging data to provide a baseline-independent assessment of ORR and progression-free survival (PFS).

Safety Monitoring: Safety is assessed through adverse events (AE), graded by Common Terminology Criteria for Adverse Events version 6.0 of the National Cancer Institute (NCI-CTCAE v6.0), physical exams, and laboratory monitoring. Special focus is placed on hematological toxicities (e.g., duration of severe neutropenia [DSN]).

Pharmacokinetics and Biomarkers:

A subset of participants in Phase IIb will undergo pharmacokinetics (PK) sampling. Exploratory analyses will investigate the relationship between biomarkers (e.g., PD-L1, BRCA1/2) and clinical outcomes.

03

Conditions studied

  • Locally Advanced Triple-negative Breast Cancer
  • Metastatic Triple-negative Breast Cancer

Keywords

  • BEBT-209
  • Metastatic Triple-Negative Breast Cancer
  • CDK4/6 Inhibitors
  • Chemotherapy
  • Phase IIb/III Clinical Study
  • Locally Advanced Triple-Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for the study:

  1. Age and gender: Female, aged 18 to 75 years (inclusive).
  2. : Voluntarily signed the written informed consent form (ICF).
  3. Diagnosis: confirmed hormone receptor (HR)-negative and human epidermal growth factor receptor 2 ()-negative locally advanced or triple-negative breast cancer (TNBC).
  4. HR-negative: \<1% of nuclei stain positive for estrogen receptor (ER) and progesterone receptor (PR) by immunohistochemistry (IHC). HER2-negative: IHC 0, 1+, or IHC 2+ with negative in situ hybridization (ISH).
  5. Prior therapy: Must have received at least one but no more than two prior systemic therapies for unresectable locally advanced or metastatic disease. Progression within 12 months of completion of /adjuvant therapy is considered one .
  6. : At least one measurable lesion according to (RECIST) version 1.1.
  7. Performance status: (ECOG) performance status of 0 or 1, with stable status within 2 weeks prior to screening (clinically insignificant decline).
  8. : At least 12 weeks.
  9. Organ function: Adequate organ and bone marrow function (no blood transfusion or growth factors within 2 weeks prior to screening):

(1) (ANC) ≥ 1,500/mm³; (2) ≥ 100,000/mm³; (3) ≥ 9 g/dL; (4) (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × (ULN) (or ≤ 5.0 × ULN with liver metastases); (5) Total ≤ 1.5 × ULN (or ≤ 3 × ULN with liver metastases); (6) Serum creatinine ≤ 1.5 × ULN or ≥ 60 mL/min (Cockcroft-Gault).

10.Toxicity recovery: Prior anti-cancer therapy toxicities resolved to ≤ grade 1 per National Cancer Institute (NCI CTCAE) version 6.0 (excluding alopecia or other stable toxicities deemed safe by the investigator).

11.: Negative serum pregnancy test within 7 days before treatment for women of . Agree to use highly effective contraception during the study and for 6 months after the last dose.

Note: The initial documentation of locally advanced or metastatic disease must be supported by , pathology, or imaging reports with specific dates. Systemic therapy includes systemic treatments for TNBC, such as chemotherapy, targeted therapy, and immunotherapy.

Exclusion criteria

Exclusion Criteria

Participants meeting any of the following criteria will be excluded:

  1. Prior treatment history: Prior treatment with gemcitabine.
  2. Prior treatment with carboplatin for unresectable locally recurrent or breast cancer (unless completed in the (neo) setting >6 months prior to first metastatic relapse).
  3. Central nervous system (CNS) metastases: Known or (including leptomeningeal metastases, spinal cord metastases, spinal cord compression, and unstable brain metastases). Participants with stable brain metastases (clinically/radiographically stable for at least 4 weeks) are eligible.
  4. Pulmonary conditions: pulmonary diseases (e.g., pulmonary embolism within 3 months, severe asthma, severe (COPD), restrictive lung disease, significant pleural effusion) or /inflammatory diseases with lung involvement. Current interstitial lung disease (ILD)/pneumonitis requiring systemic , or active ILD/pneumonitis suggested by baseline imaging.
  5. Effusion and cachexia: Uncontrolled moderate to large pleural, pericardial, or abdominal effusion requiring repeated drainage, or cachexia.
  6. Transplantation: Prior history of hematopoietic stem cell or bone marrow transplantation.
  7. Prohibited concomitant medications (within 7 days prior to first dose):

(1) Strong cytochrome P450 3A4 () inhibitors or inducers; (2) Medications known to significantly prolong the or cause torsades de pointes (e.g., quinidine, disopyramide, procainamide, sotalol).

8. for prior anti-tumor therapy: Radiotherapy or oral small-molecule targeted therapy within 14 days; cytotoxic chemotherapy within 21 days; systemic anti-tumor therapies (e.g., macromolecules, , antibody-drug conjugates (ADCs)) within 28 days; cell therapy within 3 months.

9.: Known or suspected hypersensitivity to BEBT-209, carboplatin, gemcitabine, or any of their .

10.Cardiac abnormalities: Significant (ECG) abnormalities: QTcF > 480 msec (based on the mean of triplicate ECGs if the first is >480 msec); History of long QT syndrome (personal or family); Clinically significant ventricular arrhythmia or current use of anti-arrhythmic drugs/implantable cardioverter-defibrillator (ICD).

11.Electrolyte imbalance: Uncontrolled electrolyte disturbances (e.g., hypocalcemia \<1.0 mmol/L, hypokalemia \<3.0 mmol/L, hypomagnesemia \<0.5 mmol/L) that increase QTc prolongation risk (re-screening allowed after intervention).

12.Cardiovascular/cerebrovascular disease (within 6 months):

  1. (NYHA) Class III-IV congestive heart failure or uncontrolled heart failure/coronary artery disease;
  2. Clinically significant arrhythmias (e.g., symptomatic atrial fibrillation/flutter) or v6.0 grade ≥ 3 arrhythmias;
  3. Myocardial infarction, severe/unstable angina, stroke, (TIA), symptomatic pulmonary embolism, coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI);
  4. hypertension: systolic blood pressure (SBP) > 160 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg despite ≥ 3 types of antihypertensive medications.

13.Gastrointestinal issues: Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, gastrectomy, or any malabsorption syndrome that may impair BEBT-209 absorption.

14.Active infections of clinical significance, including virus (HBV), virus (HCV), known (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases, and active syphilis infection.

Active hepatitis B is defined as positive hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) with HBV DNA above the (ULN) of the study center. Patients with HBV DNA quantification above the ULN are permitted to receive antiviral therapy prior to screening and may be enrolled once viral load decreases to within the normal range; however, anti-HBV therapy must be continued throughout the study period.

Active hepatitis C is defined as HCV RNA above the detection limit. Active syphilis infection is defined as positive treponemal antibody with positive nontreponemal test (rapid plasma reagin [RPR] or toluidine red unheated serum test [TRUST]).

15.Diabetes: Poorly controlled diabetes ( (HbA1c) ≥ 8.5%). 16.Other : Other progressive malignancies or malignancies treated within the past 5 years (excluding cured basal/squamous cell skin cancer or cervical carcinoma in situ).

17.Psychiatric/neurological conditions: Active suicidal ideation or behavior within 3 months; current neurological disorders ≥ NCI CTCAE v6.0 grade 2.

18.General exclusion: Any other severe medical, psychiatric, or laboratory abnormality that, in the investigator's opinion, increases participant risk or interferes with study results.

Terms in these criteria, in plain language(42)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
446 participants (estimated)

Study arms

  • Active comparator
    Carboplatin plus Gemcitabine(CG)

    Participants in this arm will receive carboplatin (2 \[mg/mL/min\] × \[CrCl (mL/min) + 25\]) and gemcitabine (1000 mg/m²) in 21-day cycles. Treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent.

    Drug: Carboplatin Injection · Drug: Gemcitabine Hydrochloride for Injection

  • Experimental
    BEBT-209 plus CG

    This is a phase IIb/III study. Participants in this arm will receive BEBT-209 150 mg orally on Days 1, 2, 8, and 9 of each 21-day cycle, administered as follows: Days 1 and 8: BEBT-209 administered at least 30 minutes before dinner Days 2 and 9 (chemotherapy days): BEBT-209 administered at least 30 minutes before breakfast, followed by carboplatin (2 \[mg/mL/min\] × \[CrCl (mL/min) + 25\]) and gemcitabine (1000 mg/m²) intravenously; the interval between BEBT-209 dosing and chemotherapy initiation is 4 hours ± 0.5 hours. Treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent.

    Drug: BEBT-209 capsules · Drug: Carboplatin Injection · Drug: Gemcitabine Hydrochloride for Injection

Interventions

  • Dosage: 150 mg orally per dose. Schedule: Administered on Day 1 (D1; before dinner), Day 2 (D2; before breakfast), Day 8 (D8; before dinner), and Day 9 (D9; before breakfast) of each 21-day cycle. Timing: On chemotherapy days (D2 and D9), BEBT-209 must be taken at least 30 minutes before breakfast and exactly 4 hours (±0.5 hours) prior to the start of chemotherapy. Duration: Treatment continues until progressive disease (PD), unacceptable toxicity, or withdrawal of consent. Dose adjustment: Dose reductions for BEBT-209 are not permitted.

    Also known as: KCBI-0191

  • Dosage: Intravenous infusion at AUC 2 (Calvert formula: 2 (mg/mL/min) × \[CrCl (mL/min) + 25\]). Schedule: Administered on Day 2 and Day 9 (experimental arm) or Day 1 and Day 8 (control arm) of each 21-day cycle. Precautions: Must be diluted with 5% glucose. Do not use equipment containing aluminum. Dose adjustment: May be reduced to AUC 1.5 (Calvert formula: 1.5 (mg/mL/min) × \[CrCl (mL/min) + 25\]) based on hematological toxicity. If delay exceeds 42 days, treatment must be discontinued.

    Also known as: NSC 241240

  • Dosage: Intravenous infusion at 1000 mg/m². Schedule: Administered on Day 2 and Day 9 (experimental arm) or Day 1 and Day 8 (control arm) of each 21-day cycle. Preparation: Diluted with 0.9% sodium chloride (with a gemcitabine concentration of ≤40 mg/mL); do not refrigerate after dilution. Dose adjustment: May be reduced to 800 mg/m² based on toxicity. If delay exceeds 42 days, treatment must be discontinued.

    Also known as: NSC 613327

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (Phase IIb)

    Percentage of participants achieving complete response (CR) or partial response (PR) per RECIST v1.1. This is the primary endpoint for the Phase IIb and will be assessed by both independent review committee (IRC) and investigator (INV).

    Time frame: From randomization until disease progression or end of treatment or death (up to 24 months).

  2. Overall Survival (OS) (Phase III)

    Defined as the time from the date of randomization to the date of death due to any cause. This is the primary endpoint for the Phase III.

    Time frame: From randomization until death (up to 48 months).

Secondary outcomes

  1. Objective Response Rate (ORR) per RECIST v1.1 (Phase III)

    Proportion of participants achieving complete response (CR) or partial response (PR) per RECIST v1.1. Assessed by both IRC and INV for the Phase III.

    Time frame: From randomization until disease progression or end of treatment or death (up to 24 months).

  2. Progression-Free Survival (PFS) per RECIST v1.1 (Phase IIb and Phase III)

    Time from randomization to the first documented disease progression per RECIST v1.1 or death due to any cause. Assessed by both IRC and INV for the Phase IIb and Phases III.

    Time frame: From randomization until disease progression or end of treatment or death (up to 24 months).

  3. Disease Control Rate (DCR) per RECIST v1.1 (Phase IIb and Phase III)

    Percentage of participants achieving CR, PR, or stable disease (SD) per RECIST v1.1. Assessed by both IRC and INV for the Phase IIb and Phases III.

    Time frame: From randomization until disease progression or end of treatment or death (up to 24 months).

  4. Duration of Response (DoR) per RECIST v1.1 (Phase IIb and Phase III)

    Time from the first documented objective response (CR or PR) to the first documented disease progression or death. Assessed by both IRC and INV for the Phase IIb and Phases III.

    Time frame: From the date of the first documented objective response (CR or PR) until the first documented disease progression or death (up to 24 months).

  5. Overall Survival (OS) (Phase IIb)

    Time from the date of randomization to the date of death due to any cause. This endpoint is applicable to Phase IIb.

    Time frame: From randomization until death (up to 48 months).

  6. Change from Baseline in Health-Related Quality of Life (HRQoL) (Phase IIb and Phase III)

    Change from Baseline in HRQoL. Assessed by Quality of Life Instruments for Cancer Patients-Breast Cancer (QLICP-BR) version 2.0 (v2.0) in both Phase IIb and Phase III.

    Time frame: Baseline, then at each chemotherapy visit (every 21-day cycle), at the end of treatment, and every 3 months during follow-up until death or withdrawal (up to 24 months).

  7. Adverse Events (AE) and Serious Adverse Events (SAE) (Phase IIb and Phase III)

    Incidence, severity (graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0 (v6.0), and relationship to study treatment of adverse events (AEs) and serious adverse events (SAEs) in the Phase IIb and Phase III.

    Time frame: From signing of informed consent until 30 days after the last dose.

  8. Maximum Plasma Concentration (Cmax) of BEBT-209 and its major Metabolites

    The peak plasma concentrations (Cmax) of BEBT-209 and its major metabolites on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 2 (C1D2) of each 21-day treatment cycle. Applicable only to participants enrolled in the Phase IIb pharmacokinetic (PK) substudy.

    Time frame: C1D1 (pre-dose, 1h, 2h, 4h, 6h post-dose) and C1D2 (1, 2, 4, 8, 12, 24, 36h post-dose).

  9. Time to reach Cmax (Tmax) of BEBT-209 and its major metabolites

    The time to maximum plasma concentration (Tmax) of BEBT-209 and its major metabolites on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 2 (C1D2 ) of each 21-day treatment cycle. Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: C1D1 (pre-dose, 1h, 2h, 4h, 6h post-dose) and C1D2 (1, 2, 4, 8, 12, 24, 36h post-dose).

  10. Terminal Elimination Half-life (t1/2) of BEBT-209 and its major metabolites

    The time required for the plasma concentration of BEBT-209 and its major metabolites to decrease by half on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 2 (C1D2 ) of each 21-day treatment cycle. Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: C1D1 (pre-dose, 1h, 2h, 4h, 6h post-dose) and C1D2 (1, 2, 4, 8, 12, 24, 36h post-dose).

  11. Area Under the Concentration-Time Curve (AUC) of BEBT-209 and its major Metabolites

    PK parameters calculated from blood concentration-time curves of BEBT-209 and its major Metabolites, Includes AUC from 0 to 36 hours (AUC0-36h), AUC from 0 to last measurable concentration (AUC0-t), and AUC from 0 to infinity (AUC0-∞). Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: Cycle 1 Day 1 (C1D1 ) (pre-dose, 1h, 2h, 4h, 6h post-dose) and Cycle 1 Day 2 (C1D2) (1, 2, 4, 8, 12, 24, 36h post-dose).

  12. Steady-state Maximum Concentration (Cmin,ss) of BEBT-209 and its major metabolites

    The Cmin,ss of BEBT-209 and its major metabolites on Cycle 1 Day 8 (C1D8) of each 21-day treatment cycle. Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: C1D8 (pre-dose).

  13. Steady-state Maximum Concentration (Cmax,ss) of BEBT-209 and its main metabolites

    The maximum plasma concentration of BEBT-209 and its main metabolites observed during a dosing interval at steady state on Cycle 1 Day 8 (C1D8) and Cycle 1 Day 9 (C1D9) of each 21-day treatment cycle. Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: C1D8 (pre-dose, 1h, 2h, 4h, 6h post-dose) and C1D9 (1, 2, 4, 8, 12, 24, 36h post-dose).

  14. Average Steady-state Plasma Concentration (Cav,ss) of BEBT-209 and its major metabolites

    The average concentration of BEBT-209 and its major metabolites in plasma over a dosing interval at steady state on Cycle 1 Day8 (C1D8) and Cycle 1 Day 9 (C1D9 ) of each 21-day treatment cycle. Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: C1D8 (pre-dose, 1h, 2h, 4h, 6h post-dose) and C1D9 (1, 2, 4, 8, 12, 24, 36h post-dose).

  15. Steady-state Elimination Half-life (t1/2,ss) of BEBT-209 and its metabolites

    The terminal elimination half-life of BEBT-209 and its metabolites measured under steady-state conditions on Cycle 1 Day8 (C1D8) and Cycle 1 Day 9 (C1D9) of each 21-day treatment cycle. Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: C1D8 (pre-dose, 1h, 2h, 4h, 6h post-dose) and C1D9 (1, 2, 4, 8, 12, 24, 36h post-dose).

  16. Area Under the Concentration-Time Curve steady-state (AUCss) of BEBT-209 and its Metabolites

    PK parameters calculated from blood concentration-time curves of BEBT-209 and its major Metabolites at steady-state, Includes AUC from 0 to last measurable concentration at steady-state (AUC0-t,ss), AUC from 0 to infinity at steady-state (AUC0-∞,ss). Applicable only to participants enrolled in the Phase IIb PK substudy.

    Time frame: Cycle 1 Day8 (C1D8) (pre-dose, 1h, 2h, 4h, 6h post-dose) and Cycle 1 Day 9 (C1D9 ) (1, 2, 4, 8, 12, 24, 36h post-dose).

  17. Biomarker Analysis (Phase IIb and Phase III)

    Correlation of biomarker expression (e.g., programmed death-ligand 1 \[PD-L1\], Breast Cancer Gene 1/2 \[BRCA1/2\] mutation status) with clinical efficacy and safety outcomes

    Time frame: Baseline and at disease progression (up to 36 months)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jun 2030, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 22, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Jun 2030
CompletionEst.
Dec 2030
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07544056
Lead sponsor
BeBetter Med Inc
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Jun 4, 2026
Primary completion
Jun 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 18, 2026

Study contacts

Kegang Jiang, Master
Contact
kjiang@bebettermed.com
+86-18664786382
Quchang Ouyang, PhD
principal investigator · Hunan Cancer Hospital
Qiang Liu, PhD
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BEBT-209

Start the discussion